Meningioma


Meningioma resource: https://bit.ly/2T7SqVm
Surgery on a 46-year-old female with a 2-cm, dural-based enhancing tumor along the left frontal convexity. The lesion was presumed to be a meningioma and showed serial enlargement on MRI, prompting the procedure. Pathology confirmed the tumor to be a WHO grade I meningioma. Video courtesy of Anand I. Rughani, MD, and Jeffrey E. Florman, MD.


In this episode of Cancer Newsline, we discuss meningioma, a benign brain tumor that can cause side effects ranging from decreased hearing to problems with mobility.
Request an appointment at MD Anderson by calling 1-877-632-6789 or online at: https://my.mdanderson.org/Requ....estAppointment?cmpid


Monica describes increasing difficulty with memory. After discovering the tumor, Dr. Daniel Kelly gave her peace of mind and removed the Meningioma.
https://pacificneuro.org
https://pacificneuro.org/kelly
https://pacificbraintumor.org | 310-582-7450


Hollywood stunt woman Jill Brown received an incidental diagnosis of a benign convexity meningioma brain tumor after a stunt went awry. Watch as she recounts what led her to travel across the country to have her surgery performed at The Johns Hopkins Hospital in Baltimore. Learn more at http://www.hopkinsmedicine.org/neuro. For appointments, Maryland residents should call 410-955-6406, and out-of-state residents should contact 1-855-884-6754.


Hollywood stunt woman Jill Brown received an incidental diagnosis of a benign convexity meningioma brain tumor after a stunt went awry. Watch as she recounts what led her to travel across the country to have her surgery performed at The Johns Hopkins Hospital in Baltimore. Learn more at http://www.hopkinsmedicine.org/HowFar. For appointments call 1-888-899-9420


Stephen T. Magill, MD, PhD, assistant professor of Neurological Surgery at Northwestern Medicine, discusses important clinical advances in the diagnosis and management of meningioma.
“Over the years, we have begun to develop a molecular gene panel that looks at gene expression changes and actually, with greater fidelity than methylation profiling and epigenetic changes, can predict meningioma recurrence and response to radiotherapy,” says Dr. Magill. “And that’s the first biomarker that anyone has developed to predict response to radiotherapy in meningioma.”
https://breakthroughsforphysic....ians.nm.org/neurosci